Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERAS-601 in Advanced and Progressing Chordoma
NCT06957327Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ERAS-601 in chordoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Clinical Benefit Rate at 1 year. Started Apr 2025; status: active, not recruiting.
02
Drugs
ERAS-601
03
Conditions
chordoma
Beyond the preview
Go deeper on NCT06957327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957327.